期刊
SCIENCE
卷 349, 期 6249, 页码 739-742出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aab3920
关键词
-
资金
- Rocky Mountain Veterinary Branch [NIH, National Institute of Allergy and Infectious Diseases (NIAID)]
- Division of Intramural Research, NIAID, NIH
- Public Health Agency of Canada
- Center for Security Science Program, Canada
The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively. This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据